Pre-Conference Bootcamp Day
Manufacturing & Characterization Bootcamp
Monday, October 2, 2023
9:00 am Morning Coffee & Networking
Enhancing Large Scale TIL Production: Overcoming the Quality Expansion Paradox
9:25 am Chair’s Opening Remarks
9:30 am Optimizing TIL Expansion through Closed System Culture
Synopsis
- Determining the optimal culture conditions to maximize TIL cell quality
- Leveraging a closed system to prevent external contamination
- Boosting cell growth and optimizing harvesting to enhance large-scale closed production of TIL
10:00 am Leveraging Automation to Facilitate Large Scale Manufacturing
Synopsis
- Developing technology to streamline manufacturing processes
- Utilizing these systems to remove human error and simplify TIL production
- Implementing automation to drive down costs
10:30 am Round Table: Discussing Feeder vs Feeder Free Systems to Explore Future TIL Production Methods
Synopsis
- Procuring effective allogeneic feeder cells to promote cell expansion
- Comparing efficacies of both systems to determine advantages and suitability for TIL
- Can we employ a feeder-free system to reduce toxicity and GvHD risks?
11:00 am Morning Break & Refreshments
11:30 am Engineering to Accelerate Manufacturing & Decrease Production Timeline
Synopsis
- Reducing production turnaround time to prevent tumor progression and patient deterioration
- Leveraging co-stimulants to accelerate TIL expansion
- Assessing benefits of pre-REP vs REP to generate optimal TIL growth for various tumor types
Enhancing Product Characterization to Support Applicable Product Release Assays
12:00 pm Round Table: Reinventing Potency Assays to Cater for TIL & Facilitate Regulatory Compliance
Synopsis
- Pinpointing methods to effectively quantify TIL reactivity to the tumor to define targeting power
- Classifying approaches to measure TCR diversity and repertoire to uncover target landscape for assay development
- Collaborating to distinguish successful killing assays for a heterogeneous product to measure targeting ability
12:30 pm Lunch Break & Refreshments
Exploring the Future of TIL Production to Increase Accessibility
1:30 pm Developing Off-the-Shelf TIL Technology to Increase Patient Access & Treatment Ability
Synopsis
- Powerful components of TIL (CTL) manufactured with a purity of CD8+ T cells greater than 95%: as a universal off-the-shelf TIL product, unlimited quantity can be produced
- Allogeneic universal ready-to-use TIL technology greatly expands the scope of clinical applications, does not require tumor acquisition from patients, or gene editing of TCR
- Clinical observations and experimental evidence indicate that UR-TIL can exert graft GvL or GvT therapeutic effect but avoid GvHD and encouraging clinical benefits were observed. UR-TIL can be used repeatedly or in combination
2:00 pm Bitesize Workshop: Shaping the Future of Clinical-Grade TIL Manufacturing
Synopsis
- Automated, closed and GMP-compliant TIL manufacturing
- One system, many options: Modular and flexible process to meet individual needs
- Clinical-scale sorting of TIL subsets in combination with the MACSQuant Tyto Cell Sorter